• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

    5/27/25 10:05:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email

    Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships

    SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer.

    Life365 Health is a leading developer of virtual care technology solutions that enable healthcare delivery at home. The Life365 platform addresses key care delivery challenges by providing scalable solution integration and logistics to enterprise healthcare organizations, to enable patient connectivity, engagement, and improved outcomes. Life365 is a strategic partner of Microsoft Cloud for Healthcare and the Veterans Association, serving the largest population of Veterans in the world.

    Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations, payers, and government entities.

    In his new position, Roberts will spearhead the company's strategic growth initiatives, including securing funding, building strategic partnerships, and fostering relationships with key stakeholders to accelerate Life365's market expansion and long-term success.

    "We've already benefited tremendously from Jay's strategic insights during his time as an advisor," said Life365 Founder and CEO Kent Dicks. "His deep expertise in healthcare finance and innovation, coupled with his passion for advancing medical technology, will be invaluable as we pursue our mission to safely and cost-effectively connect patients to care from the comfort of their homes."

    Roberts expressed enthusiasm about his expanded role: "Life365 stands at the forefront of healthcare innovation, leveraging advanced technologies like AI to extract actionable insights from patient-generated health data. These insights enable more proactive, preventive care models that can transform healthcare delivery. I'm excited to collaborate with Kent and our investors as Life365 revolutionizes remote patient monitoring to personalize care, improve outcomes, and enhance patient engagement across the healthcare ecosystem."

    Extensive Healthcare Leadership Experience

    Beyond his role at Life365, Roberts serves as a partner with Ventac Partners, a global catalyst in life sciences that creates breakthrough companies, bringing scientific innovation to patients worldwide. He is also a venture partner for DigiLife Fund II, where he leads fundraising, due diligence, and investment decisions alongside DigiLife team members and syndicate investment funds.

    Roberts' governance expertise extends to several prominent roles, including membership on the Board of Trustees of U.S. Pharmacopeia and service on the boards of directors for multiple healthcare companies, including Cingulate (NASDAQ:CING), Caidya Research, Veriskin, NaviPoint Health, and Vyant Bio.

    Until February 2023, Roberts served as president and CEO of Vyant Bio, an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

    Throughout his distinguished career, Roberts has held chief executive officer, chief operating officer (COO), and chief financial officer (CFO) positions for Nasdaq publicly traded companies and venture and private equity-backed healthcare technology organizations. His experience spans diagnostics, software solutions, and manufacturing companies, with involvement in more than 50 M&A and debt and equity transactions.

    Roberts previously served as CEO and COO of Cancer Genetics. Prior to that, he was CFO for VirMedica, an innovative technology solutions company.

    A current member of the Alliance of CEOs, Roberts is recognized as a thought leader and expert panelist for numerous programs and publications on topics, including "conscious capitalism," leadership and mentoring, corporate finance, mergers and acquisitions, capital formation, and healthcare innovation. He holds an MBA from the University of Maine.

    About Life365

    Life365 is a leading developer of virtual care technology solutions that enable healthcare delivery at home. The Life365 platform addresses key care delivery challenges by providing scalable solution integration and logistics to enterprise healthcare organizations, enabling patient connectivity, engagement, and improved outcomes for diverse patient populations.

    The platform serves as a single integration point that enables providers, payers, and other stakeholders to implement a proactive, virtual-first care approach to remotely engage and monitor patients with various conditions and needs, including chronic disease management, post-discharge care, and population health management.

    Led by an experienced, industry-recognized team, Life365 is a major patent holder of wearables, sensors, and patches driven by machine learning/AI, driving the next generation of scalable remote patient monitoring. Life365 serves as a strategic partner of Microsoft Cloud for Healthcare and the Veterans Administration, supporting the largest population of veterans in the world.

    For more information, visit www.life365.health.

    Media Contact:

    Kendall Paulsen | Life365

    [email protected]

    888-818-2322 x705

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/life365-appoints-healthcare-veteran-jay-roberts-as-chief-development-officer-302464588.html

    SOURCE Life365

    Get the next $CING alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    SEC Filings

    View All

    SEC Form 10-Q filed by Cingulate Inc.

    10-Q - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:56:21 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:50:51 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cingulate Inc.

    DEF 14A - Cingulate Inc. (0001862150) (Filer)

    8/15/25 4:30:24 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/22/24 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

    4 - Cingulate Inc. (0001862150) (Issuer)

    9/18/23 6:00:26 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CLO and CCO Patel Nilay Dahyabhai

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:02:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Patel Nilay Dahyabhai

    3 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CSO Silva Raul R.

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/9/25 6:00:13 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Provides Management Team Update

    Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of Directors of Cingulate Inc. ("Cingulate") announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate's Chief Financial Officer, has been appointed interim CEO to ensure business continuity and operational stability. Ms. Callahan will retain her responsibilities as Chief Financial Officer. Healthcare in

    8/15/25 9:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

    KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinet

    8/6/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

    Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

    5/27/25 10:05:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

    KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

    2/13/24 6:45:00 AM ET
    $BACK
    $CING
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CING
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/30/24 6:00:22 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care